DNDi attended the 31st Conference of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) in the session on HAT chemotherapy.

Presentations:

TARRAL Antoine, Head of HAT clinical Program, DNDi
“Fexinidazole a new oral treatment for sleeping sickness– update of development”

TARRAL Antoine, on behalf of DON Robert, Head of HAT Discovery and Preclinical Program, DNDi
“Discovery and optimization of a novel drug candidate for treatment of late-stage human african trypanosomiasis. – SCYX 7158 – “

VALVERDE Olaf, Medical Manager, DNDi
“NECT field phase IIIB trial. Primary efficacy and in-hospital safety results”

BERNHARD Sonja, Project Manager & Lead Clinical Research Associate, Swiss TPH
“Feasibility of NECT administration in rural health structures. Results from implementation in a multicentre clinical trial in the DRC”

Posters:

STRUB WOURGAFT Nathalie, presented by VALVERDE Olaf
“DNDi R&D progress to tackle sleeping sickness”

KADIMA EBEJA Augustin
“The HAT Platform: Six years of regional collaborations for sustainable results“